Increased AGE-RAGE axis stress in methamphetamine (MA) abuse and MA-induced psychosis: associations with oxidative stress and increased atherogenicity

Background and aims: Methamphetamine (MA)-induced psychosis (MIP) is associated with increased oxidative toxicity (especially lipid peroxidation) and lowered antioxidant defenses. Advanced glycation end products (AGEs) cause oxidative stress upon ligand binding to AGE receptors (RAGE). There are no data on whether MA use may cause AGE-RAGE stress, and whether the latter is associated with MIP. Methods: This case-control study recruited 60 patients with MA use disorder and 30 normal controls and measured serum levels of oxidative stress toxicity (OSTOX, lipid peroxidation), antioxidant defenses (ANTIOX), magnesium, copper, atherogenicity, and AGE, soluble RAGE (sRAGE), and computed a composite reflecting AGE-RAGE axis activity. Findings: MA dependence and use were accompanied by increased AGE, sRAGE, AGE-RAGE, OSTOX/ANTIOX, Castelli risk index 1 and atherogenic index of plasma, indicating that MA causes AGE-RAGE axis stress, oxidative damage, and atherogenicity. The severity of dependence and MA dose were strongly correlated with increased sRAGE concentrations. Increased AGE-RAGE stress was strongly associated with OSTOX, OSTOX/ANTIOX, and MA-induced intoxication symptoms, psychosis, hostility, excitation, and formal thought disorders. We found that 54.8% of the variance in MIP symptoms was explained by the regression on AGE-RAGE, the OSTOX/ANTIOX ratio, lowered magnesium, and increased copper, and that these biomarkers mediated the effects of increasing MA doses on MIP symptoms. We found that 36.0% of the variance in the atherogenicity indices was explained by OSTOX/ANTIOX, AGE-RAGE, and lowered magnesium. Conclusions: MA use causes intertwined increases in AGE-RAGE axis stress and oxidative damage, which together predict the severity of MIP symptoms and increased atherogenicity.

[1]  K. Uemura,et al.  Aggregation-prone A53T mutant of α-synuclein exaggerates methamphetamine neurotoxicity in SH-SY5Y cells: Protective role of cellular cholesterol , 2022, Toxicology reports.

[2]  M. Maes,et al.  Increased Lipid Peroxidation and Lowered Antioxidant Defenses Predict Methamphetamine Induced Psychosis , 2022, medRxiv.

[3]  D. Barbosa,et al.  Increased lipid peroxidation and lowered lipid-associated antioxidant defenses mediate the effects of the paraoxonase 1 (PON1) Q192R polymorphism on disabilities and final stroke core volume in mild and moderate stroke. , 2022, medRxiv.

[4]  R. Holms Long COVID (PASC) Is Maintained by a Self-Sustaining Pro-Inflammatory TLR4/RAGE-Loop of S100A8/A9 > TLR4/RAGE Signalling, Inducing Chronic Expression of IL-1b, IL-6 and TNFa: Anti-Inflammatory Ezrin Peptides as Potential Therapy , 2022, Immuno.

[5]  M. Maes,et al.  In Schizophrenia, the Effects of the IL-6/IL-23/Th17 Axis on Health-Related Quality of Life and Disabilities Are Partly Mediated by Generalized Cognitive Decline and the Symptomatome , 2022, medRxiv.

[6]  M. Maes,et al.  The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: A precision nomothetic psychiatry analysis , 2022, medRxiv.

[7]  M. Passarelli,et al.  Advanced Glycation End Products: A Sweet Flavor That Embitters Cardiovascular Disease , 2022, International journal of molecular sciences.

[8]  M. Coughlan,et al.  The Role of AGE-RAGE Signalling as a Modulator of Gut Permeability in Diabetes , 2022, International journal of molecular sciences.

[9]  W. Compton,et al.  Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction , 2021, Annals of the New York Academy of Sciences.

[10]  K. Kasai,et al.  Fingertip advanced glycation end products and psychotic symptoms among adolescents , 2021, npj Schizophrenia.

[11]  J. Cadet,et al.  Neurotoxicity of methamphetamine: Main effects and mechanisms , 2021, Experimental Neurology.

[12]  Michael Maes,et al.  A pathway phenotype linking metabolic, immune, oxidative, and opioid pathways with comorbid depression, atherosclerosis, and unstable angina , 2021, CNS Spectrums.

[13]  M. Maes,et al.  In (deficit) schizophrenia, a general cognitive decline partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life , 2021, CNS Spectrums.

[14]  S. Vettoretti,et al.  Sarcopenia in Chronic Kidney Disease: Focus on Advanced Glycation End Products as Mediators and Markers of Oxidative Stress , 2021, Biomedicines.

[15]  J. Erusalimsky The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes , 2021, Redox biology.

[16]  K. Prasad AGE–RAGE Stress and Coronary Artery Disease , 2021, International Journal of Angiology.

[17]  S. Sirivichayakul,et al.  Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia , 2020, Molecular Neurobiology.

[18]  Mushtaq T. Abood,et al.  Elevated of Calcium and Sodium Levels as a Result of Methamphetamine Addiction, Causesand Consequence , 2020 .

[19]  E. Melin,et al.  Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study , 2020, Lipids in health and disease.

[20]  A. Suzuki,et al.  Advanced glycation end products in musculoskeletal system and disorders. , 2020, Methods.

[21]  Byoungduck Park,et al.  Methamphetamine-Induced Neuronal Damage: Neurotoxicity and Neuroinflammation , 2020, Biomolecules & therapeutics.

[22]  H. Tan,et al.  Accumulation rate of advanced glycation end products in recent onset psychosis: A longitudinal study , 2020, Psychiatry Research.

[23]  M. Maes,et al.  Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity , 2020, Molecular Neurobiology.

[24]  J. Mayo,et al.  Redox Signaling and Advanced Glycation Endproducts (AGEs) in Diet-Related Diseases , 2020, Antioxidants.

[25]  E. London,et al.  Methamphetamine-associated psychosis: links to drug use characteristics and similarity to primary psychosis , 2020, International journal of psychiatry in clinical practice.

[26]  Yasuhiko Yamamoto,et al.  CD38, CD157, and RAGE as Molecular Determinants for Social Behavior , 2019, Cells.

[27]  S. Faraone,et al.  Prevalence and Consequences of the Nonmedical Use of Amphetamine Among Persons Calling Poison Control Centers , 2019, Journal of attention disorders.

[28]  M. Pellegrini,et al.  ZEB1 insufficiency causes corneal endothelial cell state transition and altered cellular processing , 2019, bioRxiv.

[29]  Yasuhiko Yamamoto,et al.  JNK and ATF4 as two important platforms for tumor necrosis factor‐α–stimulated shedding of receptor for advanced glycation end products , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  F. Biagioni,et al.  Epigenetic Effects Induced by Methamphetamine and Methamphetamine-Dependent Oxidative Stress , 2018, Oxidative medicine and cellular longevity.

[31]  Min Zhao,et al.  A Comparison Study of Working Memory Deficits between Patients with Methamphetamine-Associated Psychosis and Patients with Schizophrenia , 2018, General Psychiatry.

[32]  M. Nechifor Magnesium in addiction - a general view. , 2018, Magnesium research.

[33]  M. Lippman,et al.  Targeting RAGE Signaling in Inflammatory Disease. , 2018, Annual review of medicine.

[34]  R. Mcketin,et al.  A systematic review of risk factors for methamphetamine-associated psychosis , 2018, The Australian and New Zealand journal of psychiatry.

[35]  A. Keshavarzian,et al.  Colon dysregulation in methamphetamine self-administering HIV-1 transgenic rats , 2018, PloS one.

[36]  E. Bulska,et al.  Effect of Disturbances of Zinc and Copper on the Physical and Mental Health Status of Patients with Alcohol Dependence , 2018, Biological Trace Element Research.

[37]  G. Salekdeh,et al.  Advanced glycation end‐products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases , 2017, Pharmacology & therapeutics.

[38]  A. Moszczynska,et al.  Molecular, Behavioral, and Physiological Consequences of Methamphetamine Neurotoxicity: Implications for Treatment , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[39]  P. Zhu,et al.  Impact of chronic methamphetamine treatment on the atherosclerosis formation in ApoE-/- mice fed a high cholesterol diet. , 2017, Oncotarget.

[40]  V. Apostolopoulos,et al.  Methamphetamine: Effects on the brain, gut and immune system , 2017, Pharmacological research.

[41]  Meijuan Zhang,et al.  The levels of triglyceride and total cholesterol in methamphetamine dependence , 2017, Medicine.

[42]  Zheng Li,et al.  Association of Polymorphisms of the Receptor for Advanced Glycation Endproducts Gene with Schizophrenia in a Han Chinese Population , 2017, BioMed research international.

[43]  M. Memo,et al.  Nutrition and AGE-ing: Focusing on Alzheimer's Disease , 2017, Oxidative medicine and cellular longevity.

[44]  K. Kasai,et al.  The regulation of soluble receptor for AGEs contributes to carbonyl stress in schizophrenia. , 2016, Biochemical and biophysical research communications.

[45]  K. Uemura,et al.  Necroptosis-like Neuronal Cell Death Caused by Cellular Cholesterol Accumulation* , 2016, The Journal of Biological Chemistry.

[46]  Habibeh Khoshbouei,et al.  Methamphetamine Regulation of Firing Activity of Dopamine Neurons , 2016, The Journal of Neuroscience.

[47]  M. Kidd,et al.  Methamphetamine-induced psychosis: Clinical features, treatment modalities and outcomes , 2016, The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa.

[48]  Qingxin Cao,et al.  Soluble receptor for advanced glycation end products mitigates vascular dysfunction in spontaneously hypertensive rats , 2016, Molecular and Cellular Biochemistry.

[49]  M. Glomb,et al.  Pathways of the Maillard reaction under physiological conditions , 2016, Glycoconjugate Journal.

[50]  P. Zhu,et al.  Chronic administration of methamphetamine promotes atherosclerosis formation in ApoE-/- knockout mice fed normal diet. , 2015, Atherosclerosis.

[51]  V. Kakkar,et al.  Hypercholesterolemia Induced Immune Response and Inflammation on Progression of Atherosclerosis in Apobtm2SgyLdlrtm1Her/J Mice , 2015, Lipids.

[52]  M. Itokawa,et al.  Advanced glycation end products and schizophrenia: A systematic review. , 2015, Journal of psychiatric research.

[53]  C. Fontes-Ribeiro,et al.  The TNF-α/Nf-κB Signaling Pathway has a Key Role in Methamphetamine–Induced Blood–Brain Barrier Dysfunction , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[54]  H. Arai,et al.  Significance of measurements of peripheral carbonyl stress markers in a cross-sectional and longitudinal study in patients with acute-stage schizophrenia. , 2014, Schizophrenia bulletin.

[55]  M. Torres-Ramos,et al.  Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress. , 2014, CNS & neurological disorders drug targets.

[56]  Dan J Stein,et al.  The neurobiology of methamphetamine induced psychosis , 2014, Front. Hum. Neurosci..

[57]  K. Koriem,et al.  Chlorogenic and Caftaric Acids in Liver Toxicity and Oxidative Stress Induced by Methamphetamine , 2014, Journal of toxicology.

[58]  Stuart A. Collins,et al.  Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. , 2014, Life sciences.

[59]  K. Prasad Low Levels of Serum Soluble Receptors for Advanced Glycation End Products, Biomarkers for Disease State: Myth or Reality , 2014, International Journal of Angiology.

[60]  A. Simm,et al.  Role of advanced glycation end products in cellular signaling , 2014, Redox biology.

[61]  N. Hurst,et al.  Cardiac complications of adult methamphetamine exposures. , 2013, The Journal of emergency medicine.

[62]  M. Iyo,et al.  Evidence for Shared Genetic Risk Between Methamphetamine-Induced Psychosis and Schizophrenia , 2013, Neuropsychopharmacology.

[63]  A. Amad,et al.  Increased advanced glycation end-products (AGEs) assessed by skin autofluorescence in schizophrenia. , 2013, Journal of psychiatric research.

[64]  Y. Qiu,et al.  Activation of receptor for advanced glycation end products contributes to aortic remodeling and endothelial dysfunction in sinoaortic denervated rats. , 2013, Atherosclerosis.

[65]  G. Fritz,et al.  RAGE regulation and signaling in inflammation and beyond , 2013, Journal of leukocyte biology.

[66]  A. Baker,et al.  Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. , 2013, JAMA psychiatry.

[67]  Chang-li Lu,et al.  Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China. , 2013, Addictive behaviors.

[68]  E. Jönsson,et al.  Is the Gly82Ser polymorphism in the RAGE gene relevant to schizophrenia and the personality trait psychoticism? , 2012, Journal of psychiatry & neuroscience : JPN.

[69]  A. Tungtrongchitr,et al.  Alterations in malondialdehyde levels and laboratory parameters among methamphetamine abusers. , 2011, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[70]  E. Leal,et al.  Methamphetamine transiently increases the blood–brain barrier permeability in the hippocampus: Role of tight junction proteins and matrix metalloproteinase-9 , 2011, Brain Research.

[71]  H. Jo,et al.  Animal, in vitro, and ex vivo models of flow-dependent atherosclerosis: role of oxidative stress. , 2011, Antioxidants & redox signaling.

[72]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[73]  R. Bevins,et al.  Methamphetamine-Associated Psychosis , 2011, Journal of Neuroimmune Pharmacology.

[74]  F. Barale,et al.  Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with different psychiatric disorders , 2011, Neuroscience Letters.

[75]  H. Zhang,et al.  HMGB1 activates nuclear factor-κB signaling by RAGE and increases the production of TNF-α in human umbilical vein endothelial cells. , 2010, Immunobiology.

[76]  Melissa G. Piper,et al.  sRAGE Induces Human Monocyte Survival and Differentiation , 2010, The Journal of Immunology.

[77]  D. Matsuzawa,et al.  Enhanced carbonyl stress in a subpopulation of schizophrenia. , 2010, Archives of general psychiatry.

[78]  H. Zhang,et al.  Role of High-Mobility Group Box 1 Protein in the Pathogenesis of Intestinal Barrier Injury in Rats With Severe Acute Pancreatitis , 2010, Pancreas.

[79]  P. Couraud,et al.  Methamphetamine Disrupts Blood–Brain Barrier Function by Induction of Oxidative Stress in Brain Endothelial Cells , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[80]  B. Bogerts,et al.  A New Pathophysiological Aspect of S100B in Schizophrenia: Potential Regulation of S100B by Its Scavenger Soluble RAGE , 2009, Biological Psychiatry.

[81]  P. Saftig,et al.  A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[82]  J. Tiihonen,et al.  Pharmacotherapy of Methamphetamine Addiction: An Update , 2008, Substance abuse.

[83]  G. Hanson,et al.  Mechanisms of methamphetamine-induced dopaminergic neurotoxicity , 2006, The AAPS Journal.

[84]  Hiroshi Yamamoto,et al.  RAGE and Soluble RAGE: Potential Therapeutic Targets for Cardiovascular Diseases , 2007, Molecular medicine.

[85]  M. Kamal,et al.  Serum antioxidant micromineral (Cu, Zn, Fe) status of drug dependent subjects: Influence of illicit drugs and lifestyle , 2007, Substance abuse treatment, prevention, and policy.

[86]  L. Ferrucci,et al.  Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.

[87]  A. Sastry,et al.  Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. , 2007, Endocrinology.

[88]  J. Meador-Woodruff,et al.  Plasma copper, iron, ceruloplasmin and ferroxidase activity in schizophrenia , 2006, Schizophrenia Research.

[89]  Ikuko Miyazaki,et al.  Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia , 2004, Brain Research.

[90]  T. Hasegawa,et al.  Role of Tumor Necrosis Factor-α in Methamphetamine-Induced Drug Dependence and Neurotoxicity , 2004, The Journal of Neuroscience.

[91]  Yong Woo Lee,et al.  Methamphetamine induces AP‐1 and NF‐κB binding and transactivation in human brain endothelial cells , 2001, Journal of neuroscience research.

[92]  W. Slikker,et al.  Methamphetamine‐Induced Dopaminergic Neurotoxicity: Role of Peroxynitrite and Neuroprotective Role of Antioxidants and Peroxynitrite Decomposition Catalysts , 2001, Annals of the New York Academy of Sciences.

[93]  H. Meltzer,et al.  Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness , 1997, Biological Psychiatry.

[94]  B Powis,et al.  The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. , 1995, Addiction.

[95]  P. Vischer,et al.  A possible role of catecholamines in atherogenesis and subsequent complications of atherosclerosis. , 1987, Experimental pathology.

[96]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.